Immunotherapies supporting innate anti-viral immunity by decoupling IFN-exaggerated neutrophil response while reinforcing suppressor states might limit neutrophil pathogenicity and provide benefit for severe COVID-19. Here, IFNA1 is linked to COVID-19.